BCI Pharma has a huge expertise in anti-infective research. The founders have discovered and used major anti-viral drug to treat patients with HIV, HBV, HCV and bacterial infections.
BCI Pharma wants to develop a state-of-the-art platform to discover innovative and novel anti-infective agents for major unmet therapeutic needs for viral and for orphan viral diseases.
We plan to collaborate with biotech research centers to combine expertise, knowledge and resources to ensure the delivery of highly effective medicine for patients.
The company will try to find molecules able to cure chronic viral diseases as well.
It is well-know that anti-viral research is one of the most successful areas compared with cancer and the global anti-viral market is expected to reach 23 billion euros in 2015.